Cost drivers in the pharmacological treatment of interstitial lung disease.

Phillen Nozibuyiso MaqhuzuMichael KreuterThomas BahmerNicolas KahnMartin ClaussenRolf HolleLarissa Schwarzkopf

Published in: Respiratory research (2021)

Pharmacological management of ILD, in particular of IPF imposes a substantial economic burden on the healthcare system. Strategies to reduce comorbidity burden and early treatment may reduce the impact of ILDs on the healthcare system.

Keyphrases

interstitial lung disease
systemic sclerosis
idiopathic pulmonary fibrosis
rheumatoid arthritis
risk factors